Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Encaleret SCHEMBL29379644 | 1.00 | CASR (1.00) | CASRCYP2D6ADRB2 | |
| Encaleret SCHEMBL31142207 | 1.00 | CASR (1.00) | CASRCYP2D6ADRB2 | |
| Encaleret SCHEMBL482047 | 1.00 | CASR (1.00) | CASRCYP2D6ADRB2 | |
| Encaleret SCHEMBL1556246 | 1.00 | CASR (1.00) | CASRCYP2D6ADRB2 | |
| Encaleret SCHEMBL1556249 | 1.00 | CASR (1.00) | CASRCYP2D6ADRB2 | |
| Encaleret SCHEMBL24334914 | 1.00 | CASR (1.00) | CASRCYP2D6ADRB2 | |
| Encaleret SCHEMBL29410158 | 0.96 | CASR (0.93) | CASRCYP2D6ADRB2 | |
| SCHEMBL13597279 | 0.95 | CASR (0.90) | CASRCYP2D6ADRB2 | |
| SCHEMBL14129198 | 0.94 | CASR (0.88) | CASRCYP2D6ADRB2 | |
| SCHEMBL1555793 | 0.94 | CASR (0.88) | CASRCYP2D6ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022060987-A1 | TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) | CALCILYTIX THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220087961-A1 | TREATMENT METHODS OF TRIPHENYL CALCILYTIC COMPOUNDS | Cantero Therapeutics, Inc. | 2022-03-24 | — | — | US | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2412697-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID COMPOUND | Japan Tobacco, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20100286416-A1 | PRODUCTION METHOD OF CARBOXYLIC ACID COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286416-A1 | PRODUCTION METHOD OF CARBOXYLIC ACID COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286416-A1 | PRODUCTION METHOD OF CARBOXYLIC ACID COMPOUND | JAPAN TOBACCO INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1619180-B1 | CaSR ANTAGONIST | JAPAN TOBACCO INC (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| EP-1619180-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CASR 1/4885CYP2D6 3373/4885ADRB2 82/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CASR 1/4885CYP2D6 3373/4885ADRB2 82/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CASR 1/4885CYP2D6 3373/4885ADRB2 82/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | CASR 1/4885CYP2D6 1900/4885ADRB2 43/4885 |
| US-20100286416-A1 | PRODUCTION METHOD OF CARBOXYLIC ACID COMPOUND | COASY, PCCA, MCCC2 | CASR 2534/4885CYP2D6 308/4885ADRB2 3867/4885 |
| US-20220087961-A1 | TREATMENT METHODS OF TRIPHENYL CALCILYTIC COMPOUNDS | CLIC1, SLC8A1, CACNA1S | CASR 216/4885CYP2D6 2126/4885ADRB2 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.